Stocks · News reference

Sinovac Biotech Requests Hearing Following New Delisting Determination Related To 2025 Annual Report Filing

May 29, 2026, 8:08 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 17, 2026, 12:18 PMBenzinga Newsdesk
Sinovac Biotech H1 EPS $(0.84) Down From $0.06 YoY, Sales $147.079M Up From $130.270M YoY
Sinovac Biotech (NASDAQ:SVA) reported quarterly losses of $(0.84) per share. This is a 1500 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $147.079 million in
Read original at benzinga
SVA
Globenewswire IncAug 7, 2026, 9:54 AMResearchandmarkets.Com
Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players
The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.
Read original at globenewswire-inc
GSK PFE MRNA SVA SNY